HARARE, Zimbabwe – Zimbabwe has completed its first bone marrow transplant, giving patients with blood cancers and severe blood disorders access to a treatment previously available only outside the country.
A specialist team at Parirenyatwa Group of Hospitals performed an autologous stem cell transplant on Clifford Munemo, 55, from Marondera. Munemo has multiple myeloma, a cancer of plasma cells inside bone marrow. Consultant haematologist Dr Moses Chatambudza led the medical team.
The procedure marks a major shift for Zimbabwean specialist medicine. Patients requiring stem cell transplantation have historically travelled to countries such as South Africa and India. The Herald reported overseas costs ranging from US$23,000 to US$40,000 in India and reaching US$70,000 in South Africa. Munemo said his local treatment cost far less, while PSMAS covered almost all expenses.
Munemo's case also shows the severity of disease facing transplant specialists. His illness started in October 2024 with severe back pain. He drove from Marondera to hospital, then lost his ability to walk and required a wheelchair. Doctors diagnosed multiple myeloma and referred him to Chatambudza at Parirenyatwa. Treatment helped him walk again by early 2025.
Tests during June 2026 showed aggressive disease. Doctors identified stem cell transplantation as his main treatment option. Parirenyatwa admitted him on August 5 and started preparation for transplantation.
The medical team first mobilised stem cells into his bloodstream, collected them through apheresis and stored them. Doctors then administered high-dose Melphalan chemotherapy to suppress diseased marrow cells. They later returned Munemo's own stored stem cells to his bloodstream.
After 10 days in protective isolation, laboratory tests showed successful engraftment and renewed blood cell production. Doctors also provided blood transfusions and preventive treatment while his immune system recovered.
Although headlines describe the procedure as a bone marrow transplant, doctors used an autologous peripheral blood stem cell transplant. Modern transplant centres frequently collect blood-forming stem cells from circulating blood rather than removing marrow directly from bone. Medical literature describes blood-derived progenitor cells as the most common graft source for autologous and allogeneic transplants.
Munemo expressed relief as doctors prepared him for discharge.
“I am feeling positive,” he said.
His recovery gives Zimbabwe its first local clinical example of a treatment long unavailable to patients who lacked money for foreign hospitals.
The breakthrough depended on investment in equipment and specialist skills.
The National AIDS Council supplied equipment worth almost US$2 million to support blood services and renal care at Parirenyatwa. The package included a Cobas e402 analyser, an ORTHO VISION analyser and a Spectra Optia Apheresis System used to collect stem cells from peripheral blood.
NAC chief executive Dr Bernard Madzima said support for specialist equipment forms part of a wider approach linking HIV programmes with cancer and non-communicable disease services. NAC has also supported infrastructure at Mpilo Central Hospital and United Bulawayo Hospitals.
Zimbabwe's first transplant also reflects years of specialist training.
Chatambudza studied medicine at the University of Zimbabwe before specialising in haematology at the University of the Witwatersrand in South Africa. He completed advanced clinical haematology training and returned to Parirenyatwa in 2021. His work covers multiple myeloma, lymphoma, haemophilia and transfusion medicine.
His return carries significance in a health system affected by shortages of specialist doctors. Chatambudza has previously described a critical shortage of professionals treating blood cancers and other blood disorders in Zimbabwe.
Building transplant services therefore requires equipment alongside trained haematologists, nurses, laboratory scientists, pharmacists, infection-control teams and blood-bank staff.
Parirenyatwa plans a cautious expansion.
Chatambudza said the team aims to complete about 30 transplants during the next 12 months while strengthening diagnostic systems and adding equipment such as a CD34 flow cytometer.
The hospital expects referrals from every province because Parirenyatwa serves as Zimbabwe's largest referral centre.
“Hopefully, by 2030, we will be doing above 100 transplants,” Chatambudza said.
The programme targets acute and chronic leukaemias, lymphomas and multiple myeloma. Doctors also expect transplant medicine to support patients with aplastic anaemia and inherited bone marrow failure disorders.
A Zimbabwean study on aplastic anaemia published before the new service noted transplant treatment was unavailable at Parirenyatwa and overseas treatment sat beyond the financial reach of many patients.
The first procedure therefore changes more than one patient's treatment journey.
Local transplantation reduces travel, accommodation and foreign hospital costs. Families stay closer to support networks. Doctors also retain clinical experience inside Zimbabwe and train younger specialists around procedures previously handled overseas.
The development also cuts pressure on foreign currency. Zimbabwean families seeking transplant treatment abroad often need tens of thousands of United States dollars before adding flights, accommodation, food and extended stays for relatives.
President Emmerson Mnangagwa has previously urged health-sector investment which reduces overseas treatment and retains foreign currency inside Zimbabwe.
The next challenge is sustainability.
Stem cell transplantation requires strict infection control, reliable blood products, specialised medicines, laboratory monitoring and intensive follow-up. A single successful procedure proves clinical capacity at one moment. A national programme requires dependable financing, maintenance, trained staff and consistent access for patients outside Harare.
Cost will remain central.
Munemo reported a local bill far below foreign prices, but authorities have not published a standard national transplant tariff. Clear pricing, medical-aid coverage and support for poorer patients will determine whether the programme reaches families beyond those with strong insurance.
Zimbabwe also needs measurable outcomes.
Parirenyatwa should publish transplant numbers, complications, survival outcomes, waiting times and patient access by province as the programme grows. Transparent clinical reporting will help doctors improve care and give patients reliable information when deciding where to seek treatment.
For Munemo, the milestone is personal.
He entered the hospital after cancer once took away his ability to walk. He now leaves Parirenyatwa after becoming the first person to receive this form of transplant inside Zimbabwe.
For the health system, the achievement carries a larger message.
Zimbabwe has moved a highly specialised blood cancer treatment from an overseas referral problem into a local clinical service. The next measure of success will come from how many patients receive safe treatment, how affordable care becomes and whether Parirenyatwa turns one historic case into a durable national programme.
